Rosiglitazone appears to be associated withan increased risk of cardiovascular events

Clinical Diabetes

Volumn 25, Issue 4, 2007, Pages 123-124

  Pignone, Michael ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA ANALYSIS; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 37249084545     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.25.4.123     Document Type: Note

References (2)

1. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ: Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 357:28-38, 2007
2. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288, 2001